Ripretinib (DCC-2618)

Ripretinib (DCC-2618) (CAS No.: 1442472-39-0) is a synthetic small molecule kinase inhibitor classified in oncology focused chemical biology as a switch control modulator of type III receptor tyrosine kinases, primarily developed as a research tool for interrogating aberrant KIT and PDGFRA signaling in tumor biology, where it binds regulatory switch pocket regions in both wild type and mutant kinase forms to stabilize inactive conformations and suppress activation associated with downstream proliferative and survival pathways, with additional reported activity against selected kinases such as FLT3 and KDR VEGFR2 that may support broader pathway deconvolution in multikinase driven systems; in biochemical and cellular profiling it demonstrates potent inhibitory effects in the nanomolar range against KIT variants including wild type, V654A, T670I, D816H, and D816V mutants, and is therefore widely applied in mechanism of action studies, resistance mutation characterization, apoptosis and growth inhibition assays, pathway phosphorylation analyses, and translational pharmacology workflows using engineered cell lines, patient derived in vitro models, and xenograft based preclinical systems, while experimental concentrations or in vivo doses are typically selected according to study specific design, model context, and research objectives in nonclinical laboratory settings.